港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

药捷安康-B

8.805

+0.2653.10%

成交量：336.30万

成交额：2,941.79万

市值：35.92亿

市盈率：-9.85

高：9.000

开：8.550

低：8.350

收：8.540

52周最高：246.000

52周最低：8.350

股本：4.08亿

香港流通股本：3.13亿

量比：1.24

换手率：1.07%

股息：- -

股息率：- -

每股收益(LYR):-0.894

净资产收益率：-36.78%

总资产收益率：-20.32%

市净率：3.48

市盈率(LYR):-9.85

市销率: 86.17

数据加载中...

总览公司新闻资讯公告

药捷安康-B(02617)：替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验完成首例患者给药

药捷安康-B(02617.HK)：捷恩泰®(替恩戈替尼)获纳入CSCO胆道恶性肿瘤诊疗指南(2026)

药捷安康-B旗下Yochanra（Tinengotinib）获CSCO指南收录，用于晚期胆道癌治疗

药捷安康-B（02617）自主创新药捷恩泰®进入2026年CSCO胆道恶性肿瘤诊疗指南

药捷安康-B披露2026年8月股份变动月报表股本维持不变

药捷安康-B(02617.HK)发布中期业绩，净亏损9546.5万元，同比收窄22.3%

《业绩》药捷安康(02617.HK)中期亏损收窄至9,547万人民币

阿斯达克财经

药捷安康-B2026年上半年营收3,545.50万元

药捷安康-B：陈谭庆芬减持，好仓比例降至5.76%

药捷安康-B：Ghalibo (PTC) Limited减持，好仓比例降至5.76%

药捷安康-B：Morningside Venture (I) Investments Limited减持，好仓比例降至5.76%

药捷安康-B（02617）公告将于2026年8月26日召开董事会审议中期业绩

药捷安康-B：CS Capital Co., Ltd.（国投招商投资管理有限公司）减持，好仓比例降至5.85%

药捷安康-B：先进制造产业投资基金二期减持，好仓比例降至5.85%

从0到1，药捷安康-B（2617.HK）替恩戈替尼上市，以“全球首创”开启商业化元年

药捷安康首款创新药获批，去年股价曾暴涨超600港元，如今已跌破发行价

红星资本局

药捷安康-B早盘涨超12% 核心产品替恩戈替尼片获批上市

异动解读｜药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市

港股异动 | 药捷安康-B(02617.HK)高开近15% 核心产品替恩戈替尼片获批上市

药捷安康-B(02617)：捷恩泰®(替恩戈替尼片)获国家药品监督管理局批准上市

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/02617/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":8.805,"timestamp":1792742888143,"preClose":8.54,"halted":0,"volume":3363000,"delay":0,"changeRate":0.031030444964871264,"floatShares":313000000,"shares":408000000,"eps":-0.8936706478351907,"marketStatus":"未开盘","change":0.265,"latestTime":"10-23 16:08:08","open":8.55,"high":9,"low":8.35,"amount":29417855,"amplitude":0.076112,"askPrice":8.825,"askSize":8500,"bidPrice":8.805,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-0.7908679503909284,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":8.54,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":1.2356247932641409,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":313000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.893671,"volumeRatio":1.2356247932641409,"shares":408000000,"dividePrice":0,"high":9,"amplitude":0.076112,"preClose":8.54,"low":8.35,"week52Low":8.35,"pbRate":"3.48","psRate":"86.17","week52High":246,"institutionHeld":0,"latestPrice":8.805,"committee":-0.030303,"eps":-0.8936706478351907,"divideRate":0,"volume":3363000,"delay":0,"ttmEps":-0.7908679503909284,"open":8.55,"prevYearClose":114.9,"prevWeekClose":9.275,"prevMonthClose":10.94,"prevQuarterClose":10.94,"fiveDayClose":9.135,"twentyDayClose":10.61,"sixtyDayClose":9.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-10-15","current":-11.133338,"percent":0.978462,"low":-380.446233,"twenty":-177.773201,"median":-66.97175,"eighty":-13.514835,"high":-10.87103,"avg":-102.888789,"sd":96.131647,"marketCap":3720398962},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-11","current":-12.187879,"twenty":-194.548173,"median":-71.729981,"eighty":-33.11771,"marketCap":3824237184},{"date":"2026-09-18","current":-13.02239,"twenty":-188.179892,"median":-71.163303,"eighty":-16.078674,"marketCap":4091423888},{"date":"2026-09-25","current":-13.026466,"twenty":-182.801065,"median":-69.75013,"eighty":-14.040359,"marketCap":4084904388},{"date":"2026-10-02","current":-13.90794,"twenty":-181.844152,"median":-68.633717,"eighty":-13.915844,"marketCap":4365919745},{"date":"2026-10-09","current":-13.514835,"twenty":-180.193948,"median":-67.810296,"eighty":-13.738942,"marketCap":4247811842},{"date":"2026-10-15","current":-11.815946,"twenty":-177.773201,"median":-66.97175,"eighty":-13.514835,"marketCap":3720398962}],"updateTime":1792948118112},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668894069","title":"药捷安康-B(02617)：替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2668894069","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668894069?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 18:54","pubTimestamp":1789728877,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，本公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验，于近日完成首例患者给药。其中新型内分泌治疗药物虽可显著延长患者生存期，为当前mCRPC一线核心治疗方案，但绝大多数患者最终会发生获得性耐药。替恩戈替尼单一疗法已在既往接受过多线治疗的mCRPC患者显出令人鼓舞的抗肿瘤疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK1161","IBBQ","MDTX","02617","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668794056","title":"药捷安康-B(02617.HK)：捷恩泰®(替恩戈替尼)获纳入CSCO胆道恶性肿瘤诊疗指南(2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668794056","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668794056?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 18:50","pubTimestamp":1789728649,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114059583","title":"药捷安康-B旗下Yochanra（Tinengotinib）获CSCO指南收录，用于晚期胆道癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1114059583","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114059583?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 18:48","pubTimestamp":1789728510,"startTime":"0","endTime":"0","summary":"药捷安康-B传来重磅消息——其自主研发的候选药物Yochanra已被正式纳入《中国临床肿瘤学会指南》推荐，适用范围指向晚期胆道癌患者。据悉，CSCO指南是国内肿瘤诊疗领域极具权威性的参考文件，其收录与推荐，往往意味着药物的临床价值获得学界认可，也可能对其未来商业化前景产生积极影响。从研发层面看，Tinengotinib是一款多靶点激酶抑制剂，在胆道癌等难治性肿瘤适应症上展现出差异化的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153242951","title":"药捷安康-B（02617）自主创新药捷恩泰®进入2026年CSCO胆道恶性肿瘤诊疗指南","url":"https://stock-news.laohu8.com/highlight/detail?id=1153242951","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153242951?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 18:46","pubTimestamp":1789728367,"startTime":"0","endTime":"0","summary":"2026年9月18日，药捷安康-B发布自愿性公告称，公司自主研发的多靶点小分子激酶抑制剂捷恩泰已被纳入《中国临床肿瘤学会胆道恶性肿瘤诊疗指南》，获评“II级推荐 2A类”，适用于晚期胆道恶性肿瘤治疗。捷恩泰于2026年8月6日获得国家药品监督管理局附条件批准上市，适应症为既往接受过系统性治疗和FGFR抑制剂治疗，并具有FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115218058","title":"药捷安康-B披露2026年8月股份变动月报表 股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1115218058","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115218058?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 18:44","pubTimestamp":1788345846,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年9月2日发布2026年8月股份变动月报表，报告期为2026年8月1日至8月31日。根据公告披露，公司普通股H股注册股本和非上市股份注册股本分别为312,687,673股和95,230,960股，总计407,918,633股，面值均为人民币1元，均与上期保持一致。整体来看，药捷安康-B 2026年8月股本结构维持稳定，未发生新的发行或回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790637","title":"药捷安康-B(02617.HK)发布中期业绩，净亏损9546.5万元，同比收窄22.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790637?lang=zh_cn&edition=fundamental","pubTime":"2026-08-26 18:29","pubTimestamp":1787740187,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662988790","title":"《业绩》药捷安康(02617.HK)中期亏损收窄至9,547万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2662988790","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662988790?lang=zh_cn&edition=fundamental","pubTime":"2026-08-26 18:27","pubTimestamp":1787740020,"startTime":"0","endTime":"0","summary":"药捷安康(02617.HK) 公布2026年6月底止六个月中期业绩，收入3,546万人民币(下同)。亏损由上年同期1.23亿元收窄至9,547万元，每股亏损24分。不派息。(ad/)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-26 16:25。)过往派息公布日期派息事项派息内容2026/03/31末期业绩无派息2025/08/25中期业绩无派息AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250618173116178_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250618173116178_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1541029/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1541029/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["MUCmain","02617","BK1161","CNHmain","UCmain","CYB","MCNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190344185","title":"药捷安康-B2026年上半年营收3,545.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190344185","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190344185?lang=zh_cn&edition=fundamental","pubTime":"2026-08-26 18:26","pubTimestamp":1787740009,"startTime":"0","endTime":"0","summary":"本季度信息\n药捷安康-B在截至2026年6月30日止六个月实现营收3,545.50万元，上年同期无营收。报告期内毛利同为3,545.50万元，毛利率为100%。期间公司进一步优化资源投入，研发成本为1.10亿元，同比增长11.7%；管理费用为2,306.00万元，同比下降16.1%。\n业务分项\n本期收入主要来自合作及授权协议的预付款。根据财报，暂无其他业务板块的详细财务数据披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B2026年上半年营收3,545.50万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111677564","title":"药捷安康-B：陈谭庆芬减持，好仓比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111677564","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111677564?lang=zh_cn&edition=fundamental","pubTime":"2026-08-25 17:16","pubTimestamp":1787649384,"startTime":"0","endTime":"0","summary":"陈谭庆芬于2026年8月20日以每股均价10.5891港元卖出药捷安康-B股份100.00万股，涉资约1058.91万港元。陈谭庆芬此次减持前持有药捷安康-B好仓1901.84万股，占比6.08%；减持后持股量为1801.84万股，好仓比例降至5.76%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120152827","title":"药捷安康-B：Ghalibo (PTC) Limited减持，好仓比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120152827","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120152827?lang=zh_cn&edition=fundamental","pubTime":"2026-08-25 17:13","pubTimestamp":1787649224,"startTime":"0","endTime":"0","summary":"Ghalibo (PTC) Limited于2026年8月20日以每股均价10.5891港元卖出药捷安康-B股份100.00万股，涉资约1058.91万港元。Ghalibo (PTC) Limited此次减持前持有药捷安康-B好仓1901.84万股，占比6.08%；减持后持股量为1801.84万股，好仓比例降至5.76%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190623156","title":"药捷安康-B：Morningside Venture (I) Investments Limited减持，好仓比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190623156","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190623156?lang=zh_cn&edition=fundamental","pubTime":"2026-08-24 17:17","pubTimestamp":1787563066,"startTime":"0","endTime":"0","summary":"Morningside Venture (I) Investments Limited于2026年8月20日以每股均价10.5891港元卖出药捷安康-B股份100.00万股，涉资约1058.91万港元。Morningside Venture (I) Investments Limited此次减持前持有药捷安康-B好仓1901.84万股，占比6.08%；减持后持股量为1801.84万股，好仓比例降至5.76%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B：Morningside Venture (I) Investments Limited减持，好仓比例降至5.76%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136236588","title":"药捷安康-B（02617）公告将于2026年8月26日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1136236588","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136236588?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 17:01","pubTimestamp":1786698081,"startTime":"0","endTime":"0","summary":"药捷安康（南京）科技股份有限公司（02617）8月14日公告，公司董事会已决定于2026年8月26日（星期三）召开董事会会议。\n会议议程包括：  \n(i) 审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计综合中期业绩及其发布；  \n(ii) 研究宣派及派付2026年中期股息（如有）；  \n(iii) 处理其他相关事项。\n公告同时披露，截至公告日期，公司董事会成员包括：执行董事吴永谦博士、吴笛先生；非执行董事贾中新女士；独立非执行董事徐海音女士、冯维波先生及李书湃先生。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123933397","title":"药捷安康-B：CS Capital Co., Ltd.（国投招商投资管理有限公司）减持，好仓比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123933397","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123933397?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 17:15","pubTimestamp":1786353342,"startTime":"0","endTime":"0","summary":"CS Capital Co., Ltd.（国投招商投资管理有限公司）于2026年8月7日以每股均价13.74港元卖出药捷安康-B（02617）股份177.30万股，涉资约2436.10万港元。CS Capital Co., Ltd.（国投招商投资管理有限公司）此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143271311","title":"药捷安康-B：先进制造产业投资基金二期减持，好仓比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143271311","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143271311?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 17:11","pubTimestamp":1786353064,"startTime":"0","endTime":"0","summary":"Future Industry Investment Fund II (Limited Partnership) (先进制造产业投资基金二期 (有限合伙))于2026年8月7日以每股均价13.74港元卖出药捷安康-B 177.30万股H股，涉资约2436.10万港元。该基金此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660504","title":"从0到1，药捷安康-B（2617.HK）替恩戈替尼上市，以“全球首创”开启商业化元年","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660504","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660504?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 08:37","pubTimestamp":1786322238,"startTime":"0","endTime":"0","summary":"8月6日，药捷安康核心产品替恩戈替尼片（捷恩泰®）获批上市，适应症锁定在既往接受过系统性治疗和FGFR抑制剂治疗、携带FGFR2融合或重排的晚期胆管癌成人患者。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/3.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/3.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5971134","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02617","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658671398","title":"药捷安康首款创新药获批，去年股价曾暴涨超600港元，如今已跌破发行价","url":"https://stock-news.laohu8.com/highlight/detail?id=2658671398","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658671398?lang=zh_cn&edition=fundamental","pubTime":"2026-08-09 13:30","pubTimestamp":1786253443,"startTime":"0","endTime":"0","summary":"红星资本局8月9日消息，自去年股价经历“过山车”后，港股创新药公司药捷安康（2617.HK）首款药物获批上市。8月6日，据药捷安康公告，公司自主研发的新药捷恩泰(替恩戈替尼)获国家药监局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗，且具有成纤维细胞生长因子受体(FGFR)2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835908583.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835908583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","LNGR","MEDX","159992","EWH","06978","BK1574","02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660505","title":"药捷安康-B早盘涨超12% 核心产品替恩戈替尼片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660505","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657660505?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 09:45","pubTimestamp":1786067100,"startTime":"0","endTime":"0","summary":"模拟交易客户端药捷安康-B早盘高开逾28%，截至发稿，涨幅收窄，股价上涨12.06%，现报12.92港元，成交额2.26亿港元。药捷安康昨晚发布公告称，公司自主研发的1类新药捷恩泰获国家药监局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且具有FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。该疗法此前已获NMPA纳入优先审评及突破性治疗品种。据悉，该药物是药捷安康旗下首款获批上市的创新药。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-07/doc-inimmyem4200035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02617","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126093882","title":"异动解读｜药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1126093882","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126093882?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 09:30","pubTimestamp":1786066241,"startTime":"0","endTime":"0","summary":"8月7日，药捷安康-B盘中上涨21.51%，报14.04港元，成交额2036.61万港元。消息面上，公司8月6日公告，自主研发的1类新药捷恩泰获国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且携带FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者治疗。此外，替恩戈替尼全球注册性III期临床试验已于7月完成入组，商业化前景进一步明朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667795","title":"港股异动 | 药捷安康-B(02617.HK)高开近15% 核心产品替恩戈替尼片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667795","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657667795?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 09:24","pubTimestamp":1786065853,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363981","title":"药捷安康-B(02617)：捷恩泰®(替恩戈替尼片)获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363981?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 20:06","pubTimestamp":1786018007,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司自主研发的1类新药捷恩泰获得国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗，且具有成纤维细胞生长因子受体2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。此前，该疗法获NMPA纳入优先审评及突破性治疗品种。本次捷恩泰获得NMPA附条件批准上市，基于一项在中国开展的多中心、开放性、单臂、II期关键性临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IPOS","02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":129,"code":"91000000","status":"200"}]}}